All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 28 June 2018, Jeffrey A. Barnes from Massachusetts General Hospital Cancer Center, Dana‐Farber Cancer Institute, Boston, MA, USA, and colleagues published an open label phase II clinical trial (NCT01282476) on panobinostat plus rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in Hematological Oncology.
The aim of the study was to evaluate the safety and efficacy of panobinostat in combination with rituximab for the treatment of heavily pre-treated DLBCL patients who were ineligible for or relapsed after autologous stem cell transplantation (auto-SCT). The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS) rate and toxicities.
These findings showed that panobinostat plus rituximab is “well-tolerated and can induce responses in a minority of heavily pre-treated patients with DLBCL.” The inferior ORR shows an unmet need to find the population which most likely reach response to histone deactylase inhibitors.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox